Congress

Politics

Why Democrats reopened the debate about germline gene editing

By Lev Facher

Politics

Inhumane or unavoidable? As Congress scrutinizes an increase in monkey research, scientists defend its necessity

By Ruth Hailu

Politics

Facing progressive pressure, Pelosi could expand her drug pricing plan to negotiate prices for $118 billion worth of medicines

By Lev Facher

Politics

House votes to overturn Trump administration ban on fetal tissue research

By Lev Facher and Megan Thielking

Pharmalot

Pharmalittle: Trump offers to help VA negotiate for J&J drug; Senate panel to mark up drug pricing bill

By Ed Silverman

First Opinion

Why I believe the Warren-Cummings CARE Act can stop people like me from becoming opioid overdose statistics

By Ryan Hampton

Politics

House progressives challenge drug makers to come back to Capitol Hill

By Lev Facher

First Opinion

How will we pay for the coming generation of potentially curative gene therapies?

By Bill Cassidy

D.C. Diagnosis

How pharma could benefit from one of Congress’ signature drug pricing ideas

By Nicholas Florko

Pharmalot

Pharmalittle: Roche deal for Spark is delayed again; Insys files for bankruptcy

By Ed Silverman

Politics

Fed up with Washington, ALS advocates consider ACT UP’s take-no-prisoners approach

By Nicholas Florko

Politics

Top Senate Republican outlines a path forward for bipartisan drug pricing bill

By Ruth Hailu

Politics

NIH has referred 16 allegations of foreign influence on U.S. research to investigators

By Andrew Joseph

Politics

Congress revives ban on altering the DNA of human embryos used for pregnancies

By Andrew Joseph

D.C. Diagnosis

Could we nationalize insulin to make it a ‘public good’?

By Nicholas Florko

Pharmalot

Nevada adopts a law requiring drug makers to disclose costs for asthma meds, but to what end?

By Ed Silverman

Politics

Congress weighs dropping ban on altering the DNA of human embryos used for pregnancies

By Sharon Begley and Andrew Joseph

President Trump Signs "Right To Try" Act

First Opinion

‘Right-to-try’ laws provide little access to investigational drugs. We created a process that does

By Arthur Caplan

Special Report

When ‘right to try’ isn’t enough: Congress wants a single ALS patient to get a therapy never tested in humans

By Nicholas Florko

Politics

These Republicans campaigned on a bold drug-pricing pledge. Since they won, they’ve gone silent

By Lev Facher

Politics

A new Senate health package includes surprisingly aggressive drug pricing reforms

By Nicholas Florko and Lev Facher

Pharmalot

Did FDA unfairly treat Catalyst by approving a similar drug from another company?

By Ed Silverman

Pharmalot

Pharmalittle: Lawmakers push bill to punish opioid execs; Novartis will have ‘enormous leverage’ pricing its SMA drug

By Ed Silverman

D.C. Diagnosis

Scott Gottlieb is skeptical of the science behind CBD supplements

By Nicholas Florko

Pharmalot

Pharmalittle: Trump backs off a drug pricing proposal; lawmakers ask HHS for documents on Gilead’s HIV prevention pill

By Ed Silverman

Senate committee to vote on health package with ambitious plan to reduce drug prices

Pharmalittle: Azar battles White House officials; Merck seeks to expand beyond Keytruda

FDA’s overreach will harm compounding pharmacies and the patients they serve

There’s a fight brewing in Congress over pharma’s patents

Why Democrats reopened the debate about germline gene editing

Inhumane or unavoidable? As Congress scrutinizes an increase in monkey research, scientists defend its necessity

Facing progressive pressure, Pelosi could expand her drug pricing plan to negotiate prices for $118 billion worth of medicines

House votes to overturn Trump administration ban on fetal tissue research

Pharmalittle: Trump offers to help VA negotiate for J&J drug; Senate panel to mark up drug pricing bill

Why I believe the Warren-Cummings CARE Act can stop people like me from becoming opioid overdose statistics

House progressives challenge drug makers to come back to Capitol Hill

How will we pay for the coming generation of potentially curative gene therapies?

How pharma could benefit from one of Congress’ signature drug pricing ideas

Pharmalittle: Roche deal for Spark is delayed again; Insys files for bankruptcy

Fed up with Washington, ALS advocates consider ACT UP’s take-no-prisoners approach

Top Senate Republican outlines a path forward for bipartisan drug pricing bill

NIH has referred 16 allegations of foreign influence on U.S. research to investigators

Congress revives ban on altering the DNA of human embryos used for pregnancies

Could we nationalize insulin to make it a ‘public good’?

Nevada adopts a law requiring drug makers to disclose costs for asthma meds, but to what end?

Congress weighs dropping ban on altering the DNA of human embryos used for pregnancies

‘Right-to-try’ laws provide little access to investigational drugs. We created a process that does

When ‘right to try’ isn’t enough: Congress wants a single ALS patient to get a therapy never tested in humans

These Republicans campaigned on a bold drug-pricing pledge. Since they won, they’ve gone silent

A new Senate health package includes surprisingly aggressive drug pricing reforms

Did FDA unfairly treat Catalyst by approving a similar drug from another company?

Pharmalittle: Lawmakers push bill to punish opioid execs; Novartis will have ‘enormous leverage’ pricing its SMA drug

Scott Gottlieb is skeptical of the science behind CBD supplements

Pharmalittle: Trump backs off a drug pricing proposal; lawmakers ask HHS for documents on Gilead’s HIV prevention pill

Congress

Sign up for our Daily Recap newsletter